Format

Send to

Choose Destination
Indian J Cancer. 2020 Jan-Mar;57(1):13-17. doi: 10.4103/ijc.IJC_614_18.

Efficacy and safety of apatinib monotherapy in elderly patients with advanced metastatic non-small cell lung cancer.

Author information

1
Department of Cardiothoracic Surgery, Huanggang Central Hospital, Huanggang, Hubei, China.
2
Department of Oncology, The First People's Hospital of Jingzhou, Jingzhou, China.

Abstract

Objective:

No effective and definitive chemotherapeutic regimen has been established in patients with non-small cell lung cancer (NSCLC) who failed second-line treatment. The aim of this study was to evaluate apatinib, a VEGFR-2 inhibitor, as monotherapy in elderly patients with advanced metastatic NSCLC.

Methods:

We evaluated the efficacy and safety of apatinib in elderly patients (≥65 years old) with advanced metastatic NSCLC who failed second-line treatment from 2015 to 2016 in Huanggang Central Hospital. Survival analysis was performed by the Kaplan-Meier method. Toxicities were evaluated according to the National Cancer Institute Common Toxicity Criteria version 4.0.

Results:

Twenty patients were included in the present study. Two patients achieved partial response, and 9 achieved stable disease, representing a response rate of 10% and a disease control rate of 55%. Median progression-free survival and overall survival were 2.8 and 6.0 months, respectively. The toxicities associated with apatinib were generally acceptable with a total grade 3/4 toxicity of 50%.

Conclusion:

Apatinib is an optional choice as salvage treatment in elderly patients with advanced metastatic NSCLC, with modest efficacy and acceptable toxicities.

KEYWORDS:

Antiangiogenic agents; apatinib; elderly patients; non-small cell lung cancer; targeted therapy

PMID:
32129295
DOI:
10.4103/ijc.IJC_614_18
Free full text

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd
Loading ...
Support Center